Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc)

dc.contributor.author	Galle, P. R.
dc.contributor.author	Crysler, O., V
dc.contributor.author	Yarchoan, M.
dc.contributor.author	Furuse, J.
dc.contributor.author	Sukeepaisarnjaroen, W.
dc.contributor.author	Thinh, N. T.
dc.contributor.author	Masi, G.
dc.contributor.author	Lim, H. Y.
dc.contributor.author	Varela Calvo, María
dc.contributor.author	Gupta, C.
dc.contributor.author	Makowsky, M.
dc.contributor.author	Negro, A.
dc.contributor.author	Abou Alfa, G. K.
dc.date.accessioned	2024-08-26T08:33:00Z
dc.date.available	2024-08-26T08:33:00Z
dc.date.issued	2023
dc.identifier.issn	2296-5270
dc.identifier.issn	2296-5262
dc.identifier.uri	https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.4_suppl.551
dc.identifier.uri	https://hdl.handle.net/10651/74129
dc.format.extent	p. 129-129
dc.language.iso	eng
dc.relation.ispartof	Oncology Research and Treatment
dc.rights	©,
dc.source	WOS:001091456900277
dc.title	Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc)
dc.type	conference output

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.